Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
These Are the Stocks With the Largest Changes in Short Interest in July - GS
Avidity Biosciences Raises $345.1 Million From Upsized Public Offering
Express News | Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Express News | Avidity Biosciences Inc : BofA Global Research Raises Price Objective to $51 From $45
BofA Securities Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $51
Promising Phase 1/2 Results for Avidity Biosciences Reinforce Buy Rating With New Price Objective
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Avidity Biosciences (RNA) and Veeva Systems (VEEV)
Reported Earlier, Avidity Biosciences Prices $300.1M Upsized Public Offering Of 7,320,000 Common Stock At $41/Share
Express News | Avidity Biosciences Inc: Pricing of Upsized Underwritten Public Offering of 7.3 Mln Shares of Its Common Stock at a Price of $41.00 per Share
Express News | Avidity Biosciences Inc - Shares Priced at $41.00 Each
Express News | Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
Avidity Biosciences Shares Are Trading Lower After the Company Proposed a $250 Million Public Offering of Common Stock.
Express News | Avidity Biosciences Inc - It Intends to Offer and Sell $250.0 Mln of Shares of Common Stock in Underwritten Public Offering.
Express News | Avidity Biosciences Announces Proposed Public Offering of Common Stock
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $56
Avidity Biosciences: A Strong Buy on Breakthrough DMD Treatment and Solid Financials
Leerink Partners Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $64
Express News | Needham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target
Avidity Biosciences Analyst Ratings